TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21762407
Drug: Periodontal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periodontal treatment in periodontitis patients
Study: 11517272
Drug: Lorazepam (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam (2 mg orally)
Study: 22006639
Drug: Scopolamine (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scopolamine (0.4 mg, i.v.)
Study: 9268187
Drug: Ardeparin sodium
Normalized name: ardeparin sodium
DrugBank: Ardeparin (DB00407)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ardeparin sodium (10,000 anti-factor Xa U/ml with different preservatives)
Study: 9268187
Drug: Ardeparin sodium
Normalized name: ardeparin sodium
DrugBank: Ardeparin (DB00407)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ardeparin sodium (20,000 anti-factor Xa U/ml)
Study: 9268187
Drug: Ardeparin sodium
Normalized name: ardeparin sodium
DrugBank: Ardeparin (DB00407)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ardeparin sodium (all formulations)
Study: 9268187
Drug: Intravenous treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous treatment (control)
Study: 3549029
Drug: Lidocaine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (1 mg X kg‐1)
Study: 30458863
Drug: Combination gefitinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination gefitinib (250 mg daily for 7 days) and methotrexate (50 mg/m2 single dose)
Study: 30458863
Drug: Methotrexate alone
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate alone (50 mg/m2 single dose)
Study: 18840369
Drug: Rupatadine 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rupatadine 10 mg once a day for 6 days with azithromycin 500 mg on day 2 and 250 mg from day 3 to day 6
Study: 18840369
Drug: Rupatadine 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rupatadine 10 mg alone
Study: 18840369
Drug: Rupatadine 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rupatadine 10 mg with azithromycin
Study: 21125288
Drug: Intravenous abciximab
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous abciximab
Study: 29082651
Drug: telbivudine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: telbivudine (600 mg/d)
Study: 29082651
Drug: entecavir (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: entecavir (0.5 mg/d)
Study: 25098924
Drug: 8-week proton
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8-week proton pump inhibitor (PPI) therapy with 20 mg of omeprazole for 56 days
Study: 25098924
Drug: 1-week Helicobacter
Normalized name: HELICOBACTER PYLORI
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-week Helicobacter pylori eradication therapy (40 mg of omeprazole, 1,500 mg of amoxicillin, and 800 mg of clarithromycin for 7 days) followed by 7-week rebamipide treatment (300 mg for 49 days)
Study: 21067727
Drug: Oral conjugated
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral conjugated equine estrogens (0.625 mg) with oral medroxyprogesterone acetate (5 mg) on 14 of the 28 days
Study: 21067727
Drug: Natural E(2)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural E(2) gel (1.5 mg) with oral micronized P (200 mg) on 14 of the 28 days
Study: 19185243
Drug: Topical lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical lidocaine 8% pH 6.0
Study: 19185243
Drug: Topical lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical lidocaine 8%
Study: 19185243
Drug: Topical lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical lidocaine 16% given 6 times
Study: 11432535
Drug: Randomised dose-controlled
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomised dose-controlled trial (RDCT)
Study: 8625167
Drug: IL-2 and
Normalized name: IL-2
DrugBank: Human interleukin-2 (DB14865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-2 and PEG-IL-2 combination
Study: 30920645
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care (SoC) chemotherapy
Study: 28743240
Drug: Stereotactic radiosurgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic radiosurgery (SRS) with a single dose in the range of 15-24 Gy
Study: 19412613
Drug: Standardized pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized pain therapy (Group 2)
Study: 9550533
Drug: Intense nonpharmacological
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intense nonpharmacological intervention including a low-fat, high-fiber diet and regular daily physical exercise
Study: 3291938
Drug: Epostane (3-beta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epostane (3-beta hydroxy steroid dehydrogenase inhibitor)
Study: 28912050
Drug: Pancreatic enzyme
Normalized name: Pancreatic enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancreatic enzyme replacement therapy (PERT) for 28 days
Study: 24345055
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment group (n=9) - treated by the same protocol twice a day
Study: 24345055
Drug: Routine care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine care group (n=9) - received physical therapy according to daily custom protocol
Study: 12616127
Drug: Subcutaneous recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous recombinant human erythropoietin (r‐HuEPO)
Study: 3901375
Drug: Epidural saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural saline solution
Study: 26969417
Drug: ABT-436 (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-436 (1,000 mg)
Study: 22192967
Drug: Fluticasone propionate,
Normalized name: fluticasone propionate, micronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone propionate, 500 μg
Study: 22192967
Drug: Fluticasone-salmeterol combination,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone-salmeterol combination, 500/50 μg
Study: 22192967
Drug: Salmeterol, 50
Normalized name: Fluticasone-Salmeterol, 500 mcg-50 mcg/inh inhalation powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol, 50 μg
Study: 18411915
Drug: Drotaverine 80
Normalized name: drotaverin
DrugBank: Drotaverine (DB06751)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drotaverine 80 mg
Study: 31904292
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg dexamethasone added to bupivacaine and epinephrine nerve blocks
Study: 26385396
Drug: RVX-208 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: RVX-208 200 mg
Study: 11185671
Drug: Sustained-release (SR)
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release (SR) dosage form of clomipramine
Study: 11185671
Drug: Immediate-release (IR)
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release (IR) dosage form of clomipramine
Study: 9264751
Drug: Hygiene measures,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hygiene measures, water sanitation, and oral rehydration therapy
Study: 3898450
Drug: Intravenous 5-fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous 5-fluorouracil (IV 5-FU)
Study: 27555604
Drug: Oral silymarin
Normalized name: silymarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral silymarin 420 mg daily in three divided doses for 6 weeks
Study: 20194956
Drug: Daily isokinetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily isokinetic hamstring exercises starting at postoperative 3 weeks (group I)
Study: 18343263
Drug: Clopidogrel 75
Normalized name: clopidogrel 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 75 mg/d plus ASA 81 mg/d
Study: 12701778
Drug: 1 ml
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ml of Depo‐Medrol (40 mg)
Study: 12701778
Drug: 1 ml
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ml of sterile saline placebo (control)
Study: 9372647
Drug: Prednisone 20
Normalized name: prednisone 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone 20 mg/d in a prospectively tapered regimen (P)
Study: 9372647
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with prednisone 20 mg/d and cyclosporin A 5 to 7 mg/kg/d (P-CsA)
Study: 3005774
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus tamoxifen 20 mg/m2 Days 2-6 and premarin 0.625 mg Q 12-H X 3 on Day 7
Study: 3005774
Drug: Chemotherapy without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy without additional hormones
Study: 3005774
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus tamoxifen and premarin in patients with inflammatory breast cancer
Study: 6321686
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus tamoxifen and premarin
Study: 28341722
Drug: BUPI (bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: BUPI (bupivacaine 0.46%, 0.46 mg/kg)
Study: 28341722
Drug: BUPI-DEX (bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: BUPI-DEX (bupivacaine with dexmedetomidine 1 µg/kg)
Study: 28341722
Drug: BUPI-BUPRE (bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: BUPI-BUPRE (bupivacaine with buprenorphine 2.5 µg/kg)
Study: 25442243
Drug: Amoxicillin/clavulanic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/clavulanic acid 2000/125 mg
Study: 14716792
Drug: Conventional densely
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional densely woven polypropylene mesh (100‐110 g/m(2))
Study: 14716792
Drug: Lightweight composite
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lightweight composite multifilament mesh (polypropylene 27‐30 g/m(2))
Study: 9202916
Drug: Alizapride 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alizapride 100 mg
Study: 3281060
Drug: Alizapride 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alizapride 200 mg
Study: 18664303
Drug: Aripiprazole (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole (15 mg)
Study: 25366037
Drug: Glibenclamide (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glibenclamide (5 to 10 mg twice daily)
Study: 19935091
Drug: c‐pharm early
Approvals — FDA: no, EMA: no, PMDA: no
Description: c‐pharm early (sertraline at 150 mg/d)
Study: 19935091
Drug: c‐pharm late
Approvals — FDA: no, EMA: no, PMDA: no
Description: c‐pharm late (placebo initially, then sertraline at 150 mg/d)
Study: 18035205
Drug: THC/CBD oromucosal
Approvals — FDA: no, EMA: no, PMDA: no
Description: THC/CBD oromucosal spray (27 mg/mL: 25 mg/mL)
Study: 3913379
Drug: Prazosin 5
Normalized name: prazosin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin 5 mg
Study: 6932833
Drug: Prazosin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin therapy (4 weeks)
Study: 22779383
Drug: Fluoridated milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoridated milk (0.5 mgF per 189 ml carton)
Study: 19921083
Drug: Alendronate (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (5 mg daily)
Study: 7790946
Drug: Buprenorphine (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine (6 or 12 mg daily)
Study: 2134443
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (without steroid drug)
Study: 340326
Drug: Cimetidine (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (1200 mg per day for 6 weeks)
Study: 381873
Drug: Cimetidine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (400 mg twice daily)
Study: 17996996
Drug: Hib-MenCY-TT co-administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hib-MenCY-TT co-administered with DTPa-HBV-IPV and PCV7
Study: 14749690
Drug: Buprenorphine 8
Normalized name: buprenorphine 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine 8 mg daily
Study: 11919661
Drug: Buprenorphine 16
Normalized name: buprenorphine 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine 16 mg daily
Study: 2038044
Drug: Additional measures
Normalized name: MEASLES VIRUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional measures of diabetes-related health beliefs, diabetic daily hassles, perceived stress, diabetic adherence, and psychiatric symptoms
Study: 1443440
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment for 6 weeks
Study: 3134518
Drug: Long-term antihypertensive
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term antihypertensive treatment
Study: 19716683
Drug: Atomoxetine (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atomoxetine (up to 1.2 mg/kg/day)
Study: 11405286
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg risedronate as a tablet
Study: 11405286
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg risedronate as an aqueous solution
Study: 11405286
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg risedronate as an intravenous infusion
Study: 29133948
Drug: Anti-depressant medications
Normalized name: pramoxine hydrochloride Medicated Pad [Scalpicin Anti-Itch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-depressant medications (ADMs): escitalopram, sertraline, or venlafaxine-extended release for 8 weeks
Study: 27863515
Drug: Enhanced treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced treatment as usual (ETAU), n = 35
Study: 16988115
Drug: PSY+PS cookie
Normalized name: PS
DrugBank: Phosphatidyl serine (DB00144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSY+PS cookie (7.68 g/d PSY and 2.6 g/d PS)
Study: 14574660
Drug: BUN >=
Approvals — FDA: no, EMA: no, PMDA: no
Description: BUN >= 15 mg/dL (sensitive cutpoint)
Study: 14574660
Drug: BUN >=
Approvals — FDA: no, EMA: no, PMDA: no
Description: BUN >= 20 mg/dL (high-yield cutpoint)
Study: 8957978
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of EEG, MLAEP, MAP and T measures
Study: 1551309
Drug: Rice (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rice (50 g carbohydrate) eaten as part of a mixed meal (32 g protein, 20 g fat)
Study: 1551309
Drug: Glucose (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose (50 g carbohydrate) eaten as part of a mixed meal (32 g protein, 20 g fat)
Study: 1551309
Drug: Glucose (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose (50 g carbohydrate) eaten alone
Study: 19963333
Drug: Alendronate 70
Normalized name: ALENDRONATE 70MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate 70 mg once weekly for 8 weeks
Study: 12145004
Drug: SE-enriched spread
Normalized name: Selenomethionine Se-75
DrugBank: Selenomethionine Se-75 (DB09400)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SE-enriched spread (18.2 +/- 1.5 g SE spread/d, corresponding to 1.60 +/- 0.13 g SEs)
Study: 10456525
Drug: 0.2 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg/kg/day subcutaneous recombinant human growth hormone (rhGH)
Study: 526527
Drug: Different sets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Different sets of treatments
Study: 30253697
Drug: Tribulus terrestris
Normalized name: TRIBULUS TERRESTRIS
DrugBank: Tribulus terrestris (DB14358)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tribulus terrestris (3 times daily for 3 months)
Study: 17295580
Drug: Active medication
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active medication (Sertraline)
Study: 15895833
Drug: Glutamate injections
Normalized name: glutamate
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Glutamate injections (1.0 mol/L)
Study: 15895833
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline injections (0.165 mol/L)
Study: 12795239
Drug: 0.15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15 mg/kg i.v. bolus
Study: 12795239
Drug: 0.04 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.04 mg/kg i.m. injection
Study: 12795239
Drug: 0.04 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.04 mg/kg i.v. infusion
Study: 385100
Drug: Cimetidine, 1.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine, 1.6 g daily for six months
Study: 29697291
Drug: Vildagliptin (vild)
Normalized name: vildagliptin
DrugBank: Vildagliptin (DB04876)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Vildagliptin (vild) plus standard medical treatment
Study: 27733159
Drug: No statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: No statin therapy
Study: 15383370
Drug: rhIL-6 infusion
Normalized name: rhIL-15
DrugBank: Interleukin-15, human recombinant (DB17467)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhIL-6 infusion for 3 hours
Study: 6624851
Drug: Oral habilitation
Normalized name: respiratory syncytial virus pre-fusion F protein, A, recombinant, stabilized / respiratory syncytial virus pre-fusion F protein, B, recombinant, stabilized Injection [Abrysvo]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral habilitation program (sensorimotor facilitation procedures)
Study: 23116500
Drug: Orthodontic miniscrew
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orthodontic miniscrew implants
Study: 11815967
Drug: High-dose-rate (HDR)
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose-rate (HDR) intracavitary radiation therapy
Study: 11815967
Drug: Low-dose-rate (LDR)
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose-rate (LDR) intracavitary radiation therapy
Study: 10431991
Drug: Oral anticoagulant
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulant (OC) treatment
Study: 2098372
Drug: Low-dose subcutaneous
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose subcutaneous heparin (LDSH)
Study: 31102063
Drug: CBT +
Normalized name: Cannabidiol
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: CBT + Fluoxetine (COMB)
Study: 26184461
Drug: risperidone long
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: risperidone long acting injection
Study: 24819857
Drug: Topical timolol‐dorzolamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical timolol‐dorzolamide fixed‐combination drops twice daily when IOP exceeded 10 mmHg
Study: 24819857
Drug: Conventional stepwise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional stepwise treatment when IOP exceeded target pressure
Study: 17442687
Drug: Etoricoxib (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib (120 mg)
Study: 12162474
Drug: Celecoxib (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (200 mg)
Study: 12271371
Drug: Topical anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anesthesia (oxybutynin 0.4% eye drops and cocaine hydrochloride 10% eye drops)
Study: 12271371
Drug: Retrobulbar anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retrobulbar anesthesia (5 ml mepivacaine 2% injected into the retrobulbar space)
Study: 10397541
Drug: Individualized, unrestricted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized, unrestricted antiretroviral therapy
Study: 8642546
Drug: Inositol 6
Normalized name: inositol 650 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inositol 6 g daily for 5 days before the 5th or 6th ECT
Study: 11691515
Drug: Quinapril 40
Normalized name: quinapril 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril 40 mg
Study: 22607887
Drug: Early invasive
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early invasive therapy
Study: 16490806
Drug: Dapoxetine 30
Normalized name: duloxetine 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapoxetine 30 mg
Study: 1723550
Drug: KRN 8601
Normalized name: KRN-5500
DrugBank: KRN-5500 (DB15215)
Approvals — FDA: no, EMA: no, PMDA: no
Description: KRN 8601 (75 micrograms/body, subcutaneous administration)
Study: 1723550
Drug: KRN 8601
Normalized name: KRN-5500
DrugBank: KRN-5500 (DB15215)
Approvals — FDA: no, EMA: no, PMDA: no
Description: KRN 8601 (100-200 micrograms/m2, intravenous drip infusion)
Study: 7195890
Drug: Surgical-medical treatment
Normalized name: zinc pyrithione Medicated Shampoo [Head & Shoulders Damage Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical-medical treatment (internal urethrotomy with antimicrobial agents)
Study: 20051377
Drug: Sulindac 150
Normalized name: sulindac 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulindac 150 mg daily for 6 weeks
Study: 9656160
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of coumarin
Study: 8122728
Drug: Weekly donation
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly donation intervals
Study: 2548815
Drug: Nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil sodium (4 mg twice daily by inhalation)
Study: 15001966
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg rifampin for 6 days
Study: 9807607
Drug: Mivacurium 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mivacurium 0.15 mg/kg
Study: 2465710
Drug: Mivacurium 0.20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mivacurium 0.20 mg/kg
Study: 12975739
Drug: Mivacurium 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mivacurium 0.25 mg/kg
Study: 31565753
Drug: Glutamine (0.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glutamine (0.9 g kg‐1 fat‐free mass)
Study: 28487249
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of rightward prismatic adaptation (PA) and anodal transcranial direct current stimulation (tDCS) of the right motor cortex
Study: 25205323
Drug: Ferritin concentration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ferritin concentration (0.29 per log‐mg/dl)
Study: 25205323
Drug: RBP (0.27
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBP (0.27 per mg/dl)
Study: 21474643
Drug: Nebulized ceftazidime
Normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulized ceftazidime (15 mg·kg(‐1)·3 h(‐1)) and amikacin (25 mg·kg(‐1)·d(‐1))